Here’s Why Fresenius Medical Care AG (FMS) Remains Attractive

Core Insights - Ariel Global Fund achieved a +23.30% return for the year 2025, outperforming both the MSCI ACWI and MSCI ACWI Value indices, although it lagged in the fourth quarter with a +2.88% return compared to +3.29% and +3.66% for the indices respectively [1] - The positive performance was supported by moderating inflation, easing financial conditions, and resilient corporate earnings, particularly driven by U.S. mega-cap technology stocks and a strong rebound in China [1] - Management remains optimistic about international equities, citing improving corporate fundamentals and attractive valuations, while emphasizing the importance of active stock selection in a market with increasing dispersion [1] Company Insights - Fresenius Medical Care AG (NYSE:FMS) is highlighted as a key stock in the Ariel Global Fund's portfolio, specializing in dialysis products and services for chronic kidney failure patients [2] - The stock of Fresenius Medical Care AG experienced a one-month return of -5.16%, with shares trading between $20.95 and $30.46 over the past 52 weeks, closing at approximately $22.21 on March 30, 2026, with a market capitalization of about $12.80 billion [2] - Despite mixed quarterly results, Fresenius Medical Care AG showed organic growth across all segments, although earnings were affected by restructuring costs; the company is viewed as attractively positioned from a risk/reward perspective due to improving profitability and strong cash generation [3]